# ERG

Source: https://onco.cc/targets/erg/  
OnCo record `erg` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ERG (Transcriptional regulator ERG) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Prostate cancer, Non-Hodgkin lymphoma and 4 more.

## Summary

Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes genetic literature 0.61, literature 1.00, genetic association 0.03, somatic mutation 0.83, animal model 0.57). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Angiosarcoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ETS transcription factor ERG; Transcriptional regulator ERG; erg-3; p55
- Tags: cancer-genes-wave
- Symbol: ERG
- Class: oncogene
- Biology: Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure. Location: Nucleus; Cytoplasm (UniProt). Locus 21q22.2 (HGNC).
- Where found: Sarcomas: Open Targets association 0.67 with sarcoma (MONDO_0005089); Prostate cancer: Open Targets association 0.58 with prostate cancer (MONDO_0008315); Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908); Leukaemia: Open Targets association 0.56 with leukaemia (MONDO_0005059); Neuroendocrine tumours: Open Targets association 0.52 with neuroendocrine neoplasm (MONDO_0019496); Acute lymphoblastic leukaemia: Open Targets association 0.54 with acute lymphoblastic leukaemia (MONDO_0004967); CIViC evidence names this disease; Prostate cancer: gene fusion putting erg under an androgen-responsive promoter 25-46% depending on disease state

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3446: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3446
- UniProt P11308: https://www.uniprot.org/uniprotkb/P11308/entry
- NCBI Gene 2078: https://www.ncbi.nlm.nih.gov/gene/2078
- Ensembl ENSG00000157554: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157554

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Angiosarcoma](https://onco.cc/cancers/angiosarcoma/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- key papers: [Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer](https://onco.cc/key-papers/paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012/), [Integrative genomic profiling of human prostate cancer](https://onco.cc/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/), [Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours](https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/), [Punctuated evolution of prostate cancer genomes](https://onco.cc/key-papers/paper-baca-punctuated-evolution-chromoplexy-cell-2013/), [Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer](https://onco.cc/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/), [SU2C-PCF: integrative clinical genomics of advanced prostate cancer](https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/), [TCGA: the molecular taxonomy of primary prostate cancer](https://onco.cc/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/), [The long tail of oncogenic drivers in prostate cancer](https://onco.cc/key-papers/paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018/), [The mutational landscape of lethal castration-resistant prostate cancer](https://onco.cc/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/), [The TMPRSS2-ERG rearrangement, ERG expression and prostate cancer outcomes: a cohort study and meta-analysis](https://onco.cc/key-papers/paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012/), [Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression](https://onco.cc/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/)
- terms: [Chromoplexy](https://onco.cc/terms/chromoplexy/)
- biomarkers: [TMPRSS2-ERG fusion (and the other ETS rearrangements)](https://onco.cc/biomarkers/tmprss2-erg-fusion/)

---
JSON: https://onco.cc/api/v1/entities/erg.json